Menarini in-licenses three drugs from Melinta

11 October 2018
melinta-therapeutics-large

Family-controlled Italian drugmaker Menarini Group has acquired exclusive rights to commercialize meropenem/vaborbactam, oritavancin and minocycline IV in 68 countries in Europe.

Menarini has done the deal with US antibiotics developer Melinta Therapeutics (Nasdaq: MLNT), expanding on the companies’ existing commercial and co-development agreement for delafloxacin - announced in 2017 - in the same 68 markets.

These markets include Europe, Asia-Pacific including China, South Korea, and Australia (Japan excluded), and Russia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical